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Hemostasis in intracranial 
Hemorrhage
Deepak Gulati, Dharti Dua and Michel T. Torbey*
Neurology Department, The Ohio State University College of Medicine, Columbus, OH, USA
Spontaneous non-traumatic intracerebral hemorrhage (ICH) is associated with high 
morbidity and mortality throughout the world with no proven effective treatment. Majority 
of hematoma expansion occur within 4 h after symptom onset and is associated 
with early deterioration and poor clinical outcome. There is a vital role of ultra-early 
hemostatic therapy in ICH to limit hematoma expansion. Patients at risk for hematoma 
expansion are with underlying hemostatic abnormalities. Treatment strategy should 
include appropriate intervention based on the history of use of antithrombotic use or 
an underlying coagulopathy in patients with ICH. For antiplatelet-associated ICH, 
recommendation is to discontinue antiplatelet agent and transfuse platelets to those 
who will undergo neurosurgical procedure with moderate quality of evidence. For vitamin 
K antagonist-associated ICH, administration of 3-factor or 4-factor prothrombin complex 
concentrates (PCCs) rather than fresh frozen plasma to patients with INR >1.4 is strongly 
recommended. For patients with novel oral anticoagulant-associated ICH, administering 
activated charcoal to those who present within 2 h of ingestion is recommended. 
Idarucizumab, a humanized monoclonal antibody fragment against dabigatran (direct 
thrombin inhibitor) is approved by FDA for emergency situations. Administer activated 
PCC (50 U/kg) or 4-factor PCC (50 U/kg) to patients with ICH associated with direct 
thrombin inhibitors (DTI) if idarucizumab is not available or if the hemorrhage is associated 
with a DTI other than dabigatran. For factor Xa inhibitor-associated ICH, administration 
of 4-factor PCC or aPCC is preferred over recombinant FVIIa because of the lower risk 
of adverse thrombotic events.
Keywords: intracerebral hemorrhage, anticoagulants, new oral anticoagulants, reversal of anticoagulation, 
hemostasis
Spontaneous non-traumatic intracerebral hemorrhage (ICH) is associated with high morbidity 
and mortality throughout the world with no proven effective treatment (1). Of the nearly 40,000 
Americans who experienced an ICH in 1997, 35–52% were dead within 1 month and only 20% were 
living independently at 6 months (2). Although the incidence of ICH decreased over the past decade, 
case fatality and long-term morbidity remained unchanged with reported 30-day ICH mortality 
ranging from 30 to 50% (3, 4).
eARLY HeMATOMA GROwTH
Hematoma expansion and early deterioration are common within the first few hours after ICH onset 
(4). Majority of hematoma expansion occur within 4 h after symptom onset, whereas an additional 
12% of patients developed hematoma growth within the next 21 h (5). Early hematoma expansion is 
reported in 19–38% of patients with ICH and is associated with early deterioration and poor clinical 
outcome (5–7).
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Hematoma growth is seen as a crucial and independent 
determinant of both mortality and functional outcome after 
ICH. For each 10% increase in hematoma growth, there is a 5% 
increased hazard of death, a 16% greater likelihood of worsening 
by one point on the mRS, or 18% of moving from independence 
to assisted independence or from assisted independence to poor 
outcome on the Barthel Index (8). Early hematoma growth has 
gained a lot of attention as an important cause of early neuro-
logical deterioration after ICH and has been thought to be a 
therapeutic target in many ongoing trials.
RATiONALe FOR ULTRA-eARLY 
HeMOSTATiC THeRAPY FOR iCH
The three most important and consistent predictors of poor 
outcome after ICH are hematoma volume, presence of intra-
ventricular hemorrhage, and depressed level of consciousness 
(9–12). Of these, hematoma volume is the single most powerful 
predictor of 30-day mortality after ICH (12). As bleeding can 
possibly continue for several hours, it is possible that ultra-early 
hemostatic therapy may be useful.
In order to even conceive any therapeutic benefit, hemostatic 
therapy should be given as soon as possible given that hematoma 
expansion is expected in 10, 17, or 22% of patients after a 15, 
30, or 45-min treatment delay following the baseline scan (13). 
Although the challenges of stroke treatment within a narrow 
time window are well established, the feasibility of this approach 
is supported by the fact that ICH patients present to emergency 
departments earlier than ischemic stroke patients (14).
HeMOSTATiC THeRAPeUTiC APPROACH
Patients at risk for ICH are with underlying hemostatic abnormali-
ties, which include those taking oral anticoagulant drugs, antiplatelet 
agents, those with acquired or congenital coagulation factor defi-
ciencies, and those with inherited or acquired qualitative or quan-
titative platelet abnormalities. Treatment strategy should include 
appropriate intervention based on the history of use of antithrom-
botic use or an underlying coagulopathy in patients with ICH.
Platelet-Related iCH
More than 25% of patients presenting with ICH are taking anti-
platelet therapy (15). Observational studies suggest that antiplate-
let use before ICH might worsens the outcome by increasing the 
risk of early hematoma growth (16). Patients taking antiplatelet 
therapy beforehand have a 27% increased odds of death compared 
with those not taking antithrombotic drugs (17).
Platelet transfusion is potentially beneficial and used prophy-
lactically in many clinical settings. Observational studies have 
shown variable association with outcome after platelet transfu-
sion for acute ICH in patients taking antiplatelet therapy (18–20). 
The effect of platelet transfusion on ICH patients was studied in a 
recent randomized open label phase 3 trial, Platelet Transfusion 
versus Standard Care after acute stroke due to spontaneous ICH 
associated with antiplatelet therapy (PATCH). The study con-
cluded that platelet transfusion was inferior to standard of care 
for patients taking antiplatelet therapy before ICH (21). The odds 
of death and dependence at 3 months were higher in the platelet 
transfusion group (OR 2.05; 95% CI 1.18–3.56) (21). Forty-two 
percent of participants who received antiplatelet therapy had a 
serious adverse event during their hospital stay. After the findings 
of the PATCH trial, platelet transfusion cannot be recommended 
for the treatment of ICH in patients taking antiplatelet therapy 
(21). It is important though to keep in mind that most of the 
participants in PATCH had taken aspirin and relatively few had 
taken ADP inhibitors (21).
PATCH recent results appear to be contradictory to an earlier 
randomized trial of platelet transfusion in patients with ICH (22). 
This prospective, double-blind, parallel, randomized, controlled 
trial enrolled patients with acute hypertensive basal ganglia hem-
orrhages undergoing craniotomy and hematoma evacuation. In 
patients who received platelets, there was less ICH recurrence (14 
versus 35%, P = 0.02) and lower postoperative hematoma volume 
in treated groups versus the untreated group. Additionally, those 
who received platelets had a significant reduction in mortality 
compared to those who did not (15.5 versus 34.2%, P = 0.02). 
Patients who were aspirin-resistant at baseline and did not receive 
transfusion had similar outcomes to aspirin-naive patients and 
better outcomes than aspirin-sensitive patients who did not 
receive a platelet transfusion. Platelet transfusion carries signifi-
cant risks with limited benefit in ICH patients (23). Desmopressin 
(DDAVP) may be an attractive alternative.
DDAVP is an analog of vasopressin. It increases the endothelial 
release of large factor VIII: von Willebrand factor multimers and 
may also increase platelet membrane glycoprotein expression, 
promoting platelet adhesion to the endothelium (24–26). DDAVP 
has been shown to reduce bleeding time (27) and improved 
platelet function (as measured by collagen/epinephrine-closure 
time) (28) following DDAVP administration in uremic patients 
exposed to aspirin. DDAVP for antiplatelet reversal have been 
reported in one study (29). Patients with either history of aspirin 
use or reduced platelet activity received DDAVP 0.4 μg/Kg IV. 
In this study, DDAVP was well tolerated and improved platelet 
activity and low rate of hematoma growth after ICH (29). Table 1 
summarizes the Neurocritical Care Society recommendation for 
antiplatelet agent reversal (30).
vitamin K-Related iCH
The use of antithrombotic agents has increased over the last dec-
ade and is expected to continue to rise over the ensuing decades 
(31). Vitamin K antagonists (VKAs) are the most common treat-
ments for secondary stroke prevention for patients with atrial 
fibrillation. Antithrombotic-associated-ICH comprises 12–20% 
of patients with ICH (32, 33). Intracerebral hemorrhage accounts 
for the vast majority (90%) of all VKA-related deaths (34). The 
rate of taking OACs has increased with the aging population 
and increased use of anticoagulant drugs in recent decades (31, 
35). Most ICH related to VKA use occur with international 
normalizing ratios (INRs) in the recommended therapeutic 
range, although the risk of hemorrhage is further increased with 
progressive elevations of the INR (36–38). Urgent reversal of 
anticoagulation may improve outcomes, reduce mortality, and 
limit hematoma expansion (39–41).
TAbLe 1 | Guidelines for antiplatelet agent reversal.
 (1) Recommend discontinuing antiplatelet agents when in intracerebral 
hemorrhage (ICH) patients (good practice statement)
 (2) Suggest against platelet transfusion for patients with antiplatelet-
associated ICH who will not undergo a neurosurgical procedure (conditional 
recommendation, low-quality evidence)
 (3) Suggest platelet transfusion for patients with aspirin- or ADP inhibitor-
associated intracranial hemorrhage who will undergo a neurosurgical 
procedure (conditional recommendation, moderate quality of evidence)
 a. Recommend platelet function testing prior to platelet transfusion if 
possible (strong recommendation, moderate quality evidence)
 b. When platelet function testing is not readily available, empiric platelet 
transfusion may be reasonable (conditional recommendation, low-quality 
evidence)
 c. Recommend against platelet transfusion for patients with normal platelet 
function (strong recommendation, moderate quality evidence)
 (4) Suggest an initial dose of one single-donor apheresis unit of platelets. 
Platelet testing is suggested prior to repeat platelet transfusion (conditional 
recommendation, moderate quality evidence)
 (5) Suggest consideration of a single dose of desmopressin (DDAVP) in ICH 
(0.4 mcg/kg IV) associated with aspirin/COX-1 inhibitors or ADP receptor 
inhibitors (conditional recommendation, low-quality evidence)
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Several effective treatment options are available for the reversal 
of VKAs, including vitamin K, fresh frozen plasma (FFP), factor 
concentrates, and activated factors. FFP, along with vitamin K, 
has been the mainstay of treatment in U.S. for years, but more 
recently, prothrombin complex concentrates (PCCs), activated 
PCC (aPCC) factor VII inhibitor bypassing activity (FEIBA), 
and recombinant activated factor VIIa (rVIIa) have emerged as 
potential therapies.
Vitamin K
It normalizes the INR by providing the necessary substrate to syn-
thesize necessary clotting factors. Since it takes vitamin K several 
hours to be effective, it should never be used alone in the emergent 
treatment of ICH (42). It is important to administer vitamin K 
as an adjunctive therapy given its long half-life. Higher doses 
(5–10 mg) of vitamin K reverse INR more quickly than lower doses 
(43–46). Although this has not been well studied by given the fast 
rate of hematoma expansion in the first few hours after ICH, a 
large single dose of vitamin K is preferred to divided dosing (47). 
Vitamin K is more effective at INR reversal when administered 
IV as compared to similar dose administered subcutaneously (43, 
44). Although oral and IV administration of vitamin K are equally 
effective in INR reversal, reversal is faster via the IV route (43, 45). 
The infusion should be administered slowly due to the low risk of 
anaphylaxis (0.03%); however, the benefit of faster infusion and 
INR reversal justifies the risk (48, 49).
Fresh frozen plasma directly replaces the clotting factors. 
Although the data regarding its use in ICH are mixed, it is com-
monly administered with vitamin K (50–54). Given the delay 
needed to prepare FFP makes its use in acute ICH very limited. 
Goldstein et al. observed that for every 30 min of delay in the first 
dose of FFP, the odds of INR reversal within 24 h was decreased by 
20% (53). Furthermore, urgent INR reduction was only achieved 
in 9.6% of patient receiving FFP (55).
Prothrombin complex concentrates are biologically inacti-
vated, vitamin-K-dependent coagulation factors prepared from 
pooled plasma agents that are lyophilized and can be quickly 
reconstituted and administered to patients. The first 4-factor PCC 
(Kcentra, CSL Behring, King of Prussia, PA, USA), containing 
coagulation factors II, VII, IX, and X, as well as proteins C and S, 
received FDA approval in 2013 for reversal of coagulopathy from 
oral VKA therapy in adults with acute major bleeding and those 
patients requiring urgent surgery or interventional procedures.
The advantages with PCC are no need for cross matching, 
reconstituted and administered rapidly in a small volume, and 
does not transmit infectious agents. The disadvantages of FFP 
are the requirement of thawing and cross matching, allergic and 
infectious transfusion reactions, large volumes, and unable to 
achieve rapid correction of INR (53, 56). PCCs rapidly normalize 
the INR (within minutes) in patients taking warfarin (57–59). 
The rate of achieving an INR <1.3 within 30  min of complet-
ing therapy was 62.2% for PCC and 9.6% for FFP with similar 
thromboembolic events and fluid overload being more common 
with FFP (55). PCCs may increase the risk of thrombotic compli-
cations, although the risk appears low (57).
There is currently no trial to evaluate 3-factor and 4-factor 
PCCs against each other. In the international multicenter reg-
istry of over 1,500 ICH patients, patients treated with 3-factor 
PCC demonstrated improved case-fatality compared with those 
treated with 4-factor PCC (60). The target INR ranges from <1.3 
to <1.5 has been cited in various studies (61). A large multina-
tional observational study of VKA-ICH reversal demonstrated 
no significant differences in the case fatality ratios for patients 
treated with FFP compared with PCC (60). Several small studies 
have shown increase survival and reduced hematoma expansion 
with PCC (39, 41, 62, 63).
The INR Normalization in Coumadin Associated Intracerebral 
Hemorrhage (INCH) trial, a randomized controlled trial of PCC 
compared with FFP, was stopped prematurely due to clear benefit 
of PCC. Results showed that 4-factor-PCC is superior to FFP in 
normalizing the INR within 3  h in patients with VKA-related 
ICH (64).
Recombinant FVIIa (rFVIIa) has been shown to correct the INR 
more rapidly than FFP (65). rFVIIa is not currently recommended 
for routine use in warfarin reversal. Two large randomized trials 
evaluated the use of rFVIIa in ICH (66, 67). Although both trials 
showed that rFVIIa was able to limit hematoma expansion, the 
phase III trial failed to demonstrate a benefit in functional outcome 
or mortality with significantly more thrombotic events as compared 
to placebo (9 versus 4%) (66, 67). Limited data exist comparing 
PCC to rFVIIa. Current guidelines recommend against the routine 
use of rFVIIa alone for the reversal of VKAs (30). Table 2 sum-
marizes the NCS recommendations for VKA reversal (30).
New ANTiCOAGULANT MeDiCATiON-
ReLATeD iCH
New oral anticoagulants (NOACs) including direct thrombin 
inhibitors (DTIs) and factor Xa inhibitors (FXa-Is) have been 
recently approved for primary and secondary prophylaxis of 
thromboembolic conditions. The use of NOAC for systemic 
anticoagulation has increased dramatically due to their puta-
tive advantages versus warfarin, rapidly growing proportion of 
TAbLe 2 | Guidelines for vitamin K antagonists (vKAs) reversal.
 (1) Discontinue VKAs when ICH is present or suspected (good practice statement)
 (2) Urgent reversal of VKAs in patients with ICH with the following exceptions (strong recommendation, moderate quality evidence)
 a. High suspicion of ICH due to cerebral venous thrombosis (conditional recommendation, very low-quality evidence)
 b. In patients with concurrent symptomatic or life-threatening thrombosis, ischemia, heparin-induced thrombocytopenia, or DIC (good practice statement)
 (3) Administration of vitamin K as soon as possible or concomitantly with other reversal agents (strong recommendation, moderate quality evidence). The following 
dosing is recommended:
 a. One dose of vitamin K 10 mg IV
 b. Subsequent treatment should be guided by follow-up international normalizing ratios (INRs) (good practice statement)
 c. If repeat INR is still elevated C 1.4 within the first 24–48 h after reversal agent administration, redose with vitamin K 10 mg IV (good practice statement)
 (4) Administer 3-factor or 4-factor prothrombin complex concentrates (PCCs) rather than fresh frozen plasma (FFP) to patients with INR >1.4 (strong recommendation, 
moderate quality evidence)
 a. 4-factor PCC is preferred over 3-factor PCC (conditional recommendation, low-quality evidence)
 b. Suggest initial reversal with PCC alone rather than combined with FFP or recombinant FVIIa (rFVIIa) (conditional recommendation, low-quality evidence)
 c. PCC dosing should be weight-based and vary according to admission INR and type of PCC used (strong recommendation, moderate quality evidence)
 d. INR testing should be repeated soon after PCC administration (15–60 min), and serially every 6–8 h for the next 24–48 h.
 e. Subsequent treatment should be guided by follow-up INR.
 f. Repeat PCC dosing may lead to increased thrombotic complications and risk of DIC.
 g. If repeat INR is still elevated >1.4 within the first 24–48 h after initial PCC dosing, suggest further correction with FFP.
 (5) Recommend against administration of rFVIIa for the reversal of VKA (strong recommendation, low quality evidence)
 (6) If PCCs are not available or contraindicated, alternative treatment is recommended over no treatment (strong recommendation, moderate quality evidence)
 a. Treatment with FFP and vitamin K is recommended over no treatment (strong recommendation, moderate quality evidence)
 b. Suggest dosing FFP at 10–15 ml/kg IV along with one dose of vitamin K 10 mg IV (conditional recommendation, low-quality evidence)
4
Gulati et al. Hemostasis in Intracranial Hemorrhage
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 80
elderly Americans, and the expanding indications for NOAC 
medications. NOAC have a shorter half-life (5–15  h), fewer 
food and drug interactions, fixed dosing, no need for frequent 
blood monitoring, and a rapid and reliable duration to onset 
and offset (68).
Direct thrombin inhibitors carry less risk of ICH (69). In the 
Randomized Evaluation of Long-Term Anticoagulant Therapy 
(Re-Ly) trial, dabigatran had a 0.31% risk of ICH compared to 
0.76% with warfarin (70). NOAC were associated with a 47% 
odds reduction in the risk of fatal bleeding in one of the meta-
analysis of 11 randomized controlled trials compared to vitamin 
K use (71).
Although animal models have shown some benefit of PCC 
in reversing the effect of dabigatran (72, 73), a randomized trial 
of healthy volunteers failed to shown an effect of PCC on aPTT, 
ecarin clotting time (ECT), and thrombin time (TT) (74). On 
the basis of in  vitro and preclinical data, administration of 
aPCC is preferred over 4-factor PCC for patients receiving 
dabigatran (75).
Idarucizumab, a humanized monoclonal antibody fragment 
against dabigatran, completely reversed the anticoagulant activ-
ity of dabigatran in 88–98% of patients (76). In a prospective 
cohort of 90 patients receiving dabigatran who required urgent 
reversal, 5 g of IV idarucizumab normalized the dilute TT and 
ECT in 88–98% of patients within minutes. There was one 
reported thrombotic event within 72 h of administration of the 
drug. In October 2015, U.S. FDA granted accelerated approval to 
Praxbind (idarucizumab) for use in patients who are taking the 
anticoagulant Pradaxa (dabigatran) during emergency situations 
when there is a need to reverse Pradaxa’s blood-thinning effects.
Direct FXa-i
The risk of ICH for FXa-I is lower than warfarin (69). In 
ROCKET-AF (An Efficacy and Safety Study of Rivaroxaban with 
Warfarin for the Prevention of Stroke and Non-Central Nervous 
System Systemic Embolism in Patients with Non-Valvular Atrial 
Fibrillation) trial, rivaroxaban had 0.5% risk of ICH compared 
to 0.7% with warfarin (77). Similarly, in ARISTOTLE (Apixaban 
for the Prevention of Stroke in Subjects with Atrial Fibrillation) 
trial, apixaban had a 0.33% risk of ICH compared with 0.8% with 
warfarin (78).
Animal studies and limited clinical data suggest that 4-fac-
tor PCC is better for patients with refractory rivaroxaban- or 
apixaban-associated hemorrhage due to high concentrations 
of factor X contained within (79, 80). One retrospective study 
reported the use of 4-factor PCC to reverse coagulopathy second-
ary to rivaroxaban and apixaban in the setting of ICH (80).
Andexanet  alfa is a recombinant human protein (modified 
FXa protein) that binds and inactivates FXa inhibitors. It has been 
studied with rivaroxaban, apixaban, and low-molecular-weight 
heparin (81). Infusion of andexanet alfa was able to quickly nor-
malize several laboratory assays in randomized controlled trials 
of healthy elderly volunteers (82). However, it may require pro-
longed infusion because anti-FXa activity returned after stopping 
the infusion. Andexanet has no known hemostatic effects. It did 
reduce tissue factor pathway inhibitor levels, which may imply a 
prothrombotic effect (81). The ANNEXA-4 trial demonstrated 
that an initial bolus and subsequent 2-h infusion of andexanet 
substantially reduced anti-factor Xa activity in patients with acute 
major bleeding associated with FXa-I, with effective hemostasis 
occurring in 79% (83).
Ciraparantag, a synthetic water-soluble compound, binds 
directly to unfractionated and low-molecular weight heparin. It 
serves as a potential universal antidote for several different classes 
of anticoagulant drugs. The synthetic compound ciraparantag 
may prove to be an effective universal reversal agent. It was able 
to reduce bleeding in animal models and normalize coagulation 
assays in healthy volunteers given edoxaban and dabigatran with 
a single IV dose (81, 84). Results of further studies and review by 
the FDA are pending.
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If oral drug intake was within a couple hours of presentation, 
oral activated charcoal offers a low side effect treatment option for 
NOAC (85). However, caution should be exhibited given the risk of 
aspiration and potential elevated intracranial pressure induced by 
vomiting. Hemodialysis should also be considered. Hemodialysis 
is more effective with dabigatran and less so for rivaroxaban or 
apixaban because they are more highly protein bound (85). Table 3 
summarizes the NCS guidelines for reversal of NOAC (30).
CONCLUSiON
Intracerebral hemorrhage is a devastating disease associated with 
high morbidity and mortality. Although no clinical trials have 
clearly showed the benefit of prompt reversal of coagulation 
abnormalities, it is a good practice to correct these abnormalities 
as fast as possible until further data are available.
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TAbLe 3 | Guidelines for reversal of new oral anticoagulants.
Direct factor Xa inhibitors (FXa-is)
 (1) Discontinue FXa-I when ICH is present or suspected (good practice statement)
 (2) Pharmacological reversal of oral FXa-I should be guided primarily by bleeding (major or intracranial) and not primarily by laboratory testing (conditional 
recommendation, low-quality evidence)
 (3) Suggest administration of activated charcoal (50 g) to intubated ICH patients with enteral access and/or those at low risk of aspiration who present within 2 h of 
ingestion of an oral direct factor Xa inhibitor (conditional recommendation, very low-quality evidence)
 (4) Suggest administering a 4-factor prothrombin complex concentrate (PCC) (50 U/kg) or activated PCC (aPCC) (50 U/kg) if ICH occurred within 3–5 terminal half-lives 
of drug exposure or in the context of liver failure (conditional recommendation, low-quality evidence)
 (5) Suggest administering 4-factor PCC or aPCC over recombinant FVIIa (rFVIIa) because of the lower risk of adverse thrombotic events (conditional recommendation, 
low-quality evidence)
Direct thrombin inhibitors (DTis)
 (1) Discontinue DTI when ICH is present or suspected (good practice statement)
 (2) Pharmacological reversal of DTI should be guided primarily by bleeding (major or intracranial) and not primarily by laboratory testing (conditional recommendation, 
low-quality evidence)
 (3) Suggest administering activated charcoal (50 g) to intubated intracranial hemorrhage patients with enteral access and/or those at low risk of aspiration who present 
within 2 h of ingestion of an oral direct thrombin inhibitor (conditional recommendation, very low-quality evidence)
 (4) Recommend administering idarucizumab (5 g IV in two divided doses) to patients with ICH associated with dabigatran if dabigatran was administered:
 a. Within a period of 3–5 half-lives and there is no evidence of renal failure (strong recommendation, moderate quality of evidence) or
 b. There is renal insufficiency leading to continued drug exposure beyond the normal 3–5 half-lives (strong recommendation, moderate quality of evidence)
 (5) Suggest administering aPCC (50 U/kg) or 4-factor PCC (50 U/kg) to patients with ICH associated with DTI if idarucizumab is not available or if the hemorrhage is 
associated with a DTI other than dabigatran
 (6) In patients with dabigatran-associated ICH and renal insufficiency or dabigatran overdose, suggest hemodialysis if idarucizumab is not available (conditional 
recommendation, low-quality data)
 (7) In patients with dabigatran-associated ICH who have already been treated with idarucizumab, PCC, or aPCC, with ongoing evidence of clinically significant bleeding, 
we suggest consideration of redosing idarucizumab and/or hemodialysis (Conditional recommendation, low-quality evidence)
 (8) Recommend against administration of rFVIIa or FFP in direct thrombin inhibitor-related intracranial hemorrhage (strong recommendation, low-quality evidence)
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